Sino Biopharmaceutical (HKG:1177) has obtained marketing approval for its eribulin mesilate injection from China's National Medical Products Administration, a Wednesday bourse filing said.

The drug is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have received at least two chemotherapeutic regimens, according to the pharmaceutical company.